Changes in anti-TNF: Is this always justified?;Cambios entre anti-TNF, ¿están siempre justificados?

Reumatologia Clinica

Volumn 4, Issue 3, 2008, Pages 87-89

  Carmona, Loreto ^a  

^a UNIDAD DE INVESTIGACIÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ANTIBODY;

COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG INDICATION; EDITORIAL; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY;

EID: 45849130139     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/S1699-258X(08)71809-6     Document Type: Editorial

References (11)

1. Descalzo M, Montero D, Erra A, Marsal S, Fernandez Castro M, Mulero J, et al. Spanish registry for adverse events of biological therapy in rheumatic diseases (BIOBADASER): State report, January 26th, 2006. Reumatol Clin. 2007;3:4-20.
2. Rahman MU, Strusberg I, Geusens P, Berman A, Yocum D, Baker D, et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66:1233-8.
3. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275-85.
4. Schwartzman S, Morgan GJJ. Does route of administration affect the outcome of TNF antagonist therapy? Arthritis Res Ther. 2004;6 Suppl 2:S19-23.
5. Sociedad Española de Reumatología. Guía de Práctica Clínica para el Manejo de la Artritis Reumatoide en España. 2007 [citado 3 Mar 2008]. Disponible en: www.ser.es
6. Carmona L, Ortiz A, Abad MA. How good is to switch between biologics? A systematic review of the literature. Acta Reumatol Port. 2007;32:113-28.
7. Kamal KM, Madhavan SS, Hornsby JA, Miller LA, Kavookjian J, Scott V. Use of tumor necrosis factor inhibitors in rheumatoid arthritis: a national survey of practicing United States rheumatologists. Jt Bone Spine. 2006;73:718-24.
8. Rodriguez-Valverde V, Caliz Caliz R, Alvaro-Gracia Alvaro J, Marenco de la Fuente J, Mulero Mendoza J, Tornero Molina J, et al. Update of the Consensus of the Spanish Society of Rheumatology on biological therapy in rheumatoid arthritis. Reumatol Clin. 2006;2:52-9.
9. Fautrel B, Pham T, Mouterde G, Le Loet X, Goupille P, Guillemin F, et al. Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis. Jt Bone Spine. 2007;74:627-37.
10. Jerram S, Butt S, Gadsby K, Deighton C. Discrepancies between the EULAR response criteria and the NICE guidelines for continuation of anti-TNF therapy in RA: a cause for concern? Rheumatology (Oxford). 2008;47:180-2.
11. Carmona L, Gomez-Reino JJ. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther. 2006;8:72